Show simple item record

dc.contributor.authorOkidi, Ronald
dc.contributor.authorOpira, Cyprian
dc.contributor.authorDa Consolação Sambo, Vanusa
dc.contributor.authorAchola, Caroline
dc.contributor.authorOgwang, David Martin
dc.date.accessioned2022-04-29T15:11:49Z
dc.date.available2022-04-29T15:11:49Z
dc.date.issued2020
dc.identifier.citationOkidi R, Opira C, Sambo VD-C, Achola C , Ogwang DM. Prostate hyperplasia in St Mary’s Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy. Afri Health Sci. 2020;20(3): 1259-1263. https://dx.doi.org/10.4314/ ahs.v20i3.30en_US
dc.identifier.urihttps://dx.doi.org/10.4314/ ahs.v20i3.30
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/2991
dc.description.abstractProstate cancer is the second commonest cancer in men worldwide. At present, every patient with lower urinary tract symptoms (LUTS) in St. Mary’s Hospital Lacor is undergoing prostate biopsy regardless of the prostate specific antigen (PSA) level. We sought to determine the association between PSA and malignant prostate histology. Methods: This was a retrospective study. Data on age, PSA, prostate volume and prostate histology reported between Jan 2012 and Dec 2019 were retrieved from St. Mary’s Hospital Lacor archive and analyzed using STATA SE/13.0. Results: Records of 97 patients with LUTS was analyzed. The median (range) age of the patients was 71 (43-100) years. Median (range) of prostate volume was 91.8 (8.0-360.0) cc. Overall, PSA ranged from 0.21 to 399.2 ng/ml. Prostate histology showed 3.1% acinar adenocarcinoma, 24.7% adenocarcinoma and 72.2% benign prostatic hyperplasia. The median PSA amongst patients with malignant and non-malignant prostates were 15.8 ng/ml and 6.07 ng/ml respectively. Serum PSA level was significantly higher in patients with malignant prostate histology (Difference of mean= 9.7; p=0.001). Conclusion: Patients with LUTS and PSA levels of 15ng/ml or more were more likely to have malignant prostate histology.en_US
dc.language.isoenen_US
dc.publisherAfri Health Sci.en_US
dc.subjectProstate specific antigenen_US
dc.subjectProstate canceren_US
dc.titleProstate hyperplasia in St Mary’s Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancyen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record